Case presentation A female infant weighing 1870 g was delivered by semi-elective Caesarean section following the spontaneous onset of preterm labour at 32 þ 4 weeks gestation. The pregnancy had been uncomplicated until this point and foetal tachycardia was not noted at any stage. The mother was a 45-year-old Para 2 þ 0 with a past medical history of autoimmune endocrine diseases. These included long-duration type I diabetes mellitus, which was complicated by proliferative retinopathy and diabetic nephropathy, and thyrotoxicosis secondary to Graves' disease which had been treated with radioactive iodine therapy many years previously, resulting in permanent hypothyroidism.
The infant was born in good condition and no resuscitation was required. Within an hour of delivery a purpuric rash emerged on the trunk, becoming generalized thereafter. Icterus and hepatosplenomegaly were noted. Initial laboratory analysis revealed abnormal haematological parameters (platelets 20 Â 10 9 /l and a leucocytosis (70.2 Â 10 9 /l on automated blood count, later shown to represent increased circulating nucleated red cells)), a coagulopathy (prothrombin time (PT) 20 s, activated partial thromboplastin time (APTT) >180 s, fibrinogen 0.8 g/l) and abnormal liver biochemistry (aspartate aminotransferase (AST) 1111 U/l, alanine aminotransferase (ALT) 186 U/l, alkaline phosphatase (ALP) 1921 U/l, gamma glutaryl transferase (GGT) 46 U/l, Albumin 26 g/l, total serum Bilirubin 300 mmol/l (conjugated fraction 99 mmol/l)). The infant was irritable, apyrexial, tachycardic (heart rate (HR) 160) and tachypnoeic (respiratory rate (RR) 100/min), but had no oxygen requirement (S a O 2 >96% in air).
The provisional differential diagnosis included congenital infection, particularly cytomegalovirus (CMV) infection. Congenital leukaemia was also considered but rejected on the basis of the haematologist's review of the peripheral blood film. A clean catch urine, throat swab, cerebro-spinal fluid and venous blood were sent for laboratory analysis. Tests for CMV, herpes simplex, toxoplasma, Epstein-Barr virus and enteroviruses were negative.
Initial management comprised a pooled platelet transfusion, fresh-frozen plasma, cryoprecipitate, intravenous vitamin K, phototherapy and empirical antibiotic treatment. Liver function tests initially improved but thereafter deteriorated with persistent hyperbilirubinaemia and elevated serum transaminase concentrations (AST>ALT). Metabolic tests for causes of the hepatic dysfunction were unyielding. Abdominal ultrasound confirmed the presence of hepatosplenomegaly but did not suggest extrahepatic biliary obstruction. The infant was discussed with the regional Gastroenterology team who advised that a liver biopsy would be the most informative investigation and transfer to the nearby tertiary paediatric centre was undertaken. Thyroid function tests, which were requested on day 5 of life in view of the mother's past medical history, revealed that the infant was suffering from congenital thyrotoxicosis (free T4>77 pmol/l (9 to 26), total T3>9.24 (1.2 to 2.6) nmol/l, thyroid-stimulating hormone (TSH) <0.01 mU/l (0.5 to 5.0)). Clinical review following the diagnosis did not elicit a palpable goitre or dysthyroid eye disease.
The infant was treated with anti-thyroid medication (carbimazole), b-blockade (propranolol) and potassium iodate (Lugol's iodine solution). Ursodeoxycholic acid and fat-soluble vitamin supplements were prescribed in view of persisting conjugated hyperbilirubinaemia. She was discharged home on day 49 of life with free thyroid hormone concentrations within normal limits and arrangements for medical and neuro-developmental follow-up in place.
Discussion Congenital hyperthyroidism is rare with an incidence of clinical thyrotoxicosis estimated at 1/50 000. 1 The majority of cases are associated with maternal Graves' disease but other types of maternal autoimmune thyroid disease can be causative. 2 Clinical signs can include tachycardia, hyperkinesis and irritability, frequent loose stools and poor weight gain. Dysthyroid eye disease and palpable goitre have been reported relatively frequently. 3 Congestive cardiac failure is not uncommon 3 and there is an association with pulmonary hypertension. 4 The case detailed above illustrates that congenital thyrotoxicosis may not present as classically described. The infant we report displayed atypical signs closely resembling congenital viral infection. Petechiae and purpura secondary to thrombocytopenia, 3, 5, 6 hepatosplenomegaly 3, 6 and conjugated hyperbilirubinaemia 5 have been reported previously. Gross and persistent elevation of the AST and alkaline phosphatase, and a coagulopathy of the degree observed have not, to the best of our knowledge, been reported to date.
The foetal thyroid gland is the first endocrine gland to form during embryogenesis and has the ability to synthesize thyroid hormones from 12 weeks gestation. Congenital thyrotoxicosis occurs due to transplacental passage of maternal thyroid receptor antibodies (TRAb) from a mother who has had Graves' disease at some stage during her life. These long-acting immunoglobulin G antibodies bind to the foetal TSH receptor, mimicking the effect of TSH, and stimulate the thyroid gland to synthesize and release excess concentrations of thyroid hormones. Passage of antibodies from mother to foetus increases as pregnancy progresses and thus foetal thyrotoxicosis worsens with gestation, becoming most clinically apparent by the third trimester. It is possible to monitor foetal thyroid status indirectly using surrogates such as heart rate and thyroid volume (ultrasound), or directly by measuring foetal thyroid function on blood obtained by cordocentesis. This latter method is by far the most accurate but carries a small but significant risk (0.8 to 1.0%) of inducing miscarriage, 7 which must be balanced against the absolute risk of thyrotoxicosis to the foetus. Monitoring foetal thyroid status affords the option of in utero treatment with can take two forms. Antithyroid medication given to the mother crosses the placenta and has a therapeutic effect on the foetus. Alternatively, iodine can be instilled into the amniotic fluid, again carrying a risk of foetal loss.
Thyroid function tests taken in the first 2 days of life may be misleading as a result of physiological changes in thyroid hormone levels. Reliable interpretation is possible from 48 h onwards. In retrospect, had we investigated at this stage, the diagnosis would have been made earlier.
Women who have previously experienced thyrotoxicosis as a consequence of Graves' disease continue to produce TRAbs indefinitely. Consequently, the development of congenital thyrotoxicosis is independent of maternal thyroid function during pregnancy and offspring of women rendered permanently hypothyroid by ablative treatments such as radioiodine or subtotal thyroidectomy many years before remain at increased risk. The present case demonstrates that this information is underrecognized in clinical practice, compounding the already difficult diagnosis of congenital thyrotoxicosis.
A correlation between maternal TRAb concentration and likelihood of development of foetal thyrotoxicosis has been proposed 1 and knowledge of TRAb concentrations in pregnant women currently or previously affected by Graves' disease may be of clinical value. However, maternal clinical surrogates of TRAb positivity such as Graves' orbitopathy (dysthyroid eye disease) and infiltrative dermopathy (pretibial myxoedema) 8 may be equally useful. Given that congenital thyrotoxicosis complicates only 1% of at-risk pregnancies 1 the cost-efficacy of measuring TRAb concentrations remains open to question.
Congenital thyrotoxicosis is a self-limiting illness, the duration being directly related to the persistence of TRAbs which are cleared from the neonatal circulation over time. By 4 months of age most affected infants have no detectable antibodies, are clinically euthyroid and are not on anti-thyroid medication. 2 Untreated, congenital thyrotoxicosis carries a mortality of approximately 25%, 1 with death occurring most frequently as a result of cardiac failure or tracheal compression as a consequence of goitre.
Treatment of congenital hyperthyroidism comprises three main strategies. Anti-thyroid medications (thionamides) such as carbimazole and propylthiouracil (PTU) have multiple inhibitory actions on the thyroid but do not act rapidly. PTU may be favoured because it also acts peripherally to inhibit conversion of T4 to the more active T3. An infrequent adverse effect of the thionamides is hepatotoxicity and administration in the face of severe liver disease must be undertaken with extreme care. Iodine, administered orally as a saturated solution of potassium iodate, has a more rapid effect on thyroid hormone concentrations but breakthrough and recurrent thyrotoxicosis may occur after just 10 to 14 days. b-Blockers have a role in alleviating the symptoms of hyperthyroidism by reducing end organ sensitivity to the increased concentration of circulating catecholamines.
In summary, congenital thyrotoxicosis is a rare but potentially fatal condition, which may masquerade as other clinical disorders in the newborn. To our knowledge, this is the only reported case where liver function and coagulation have been so deranged as to prompt consideration of liver biopsy. Identification of infants at high risk of congenital thyrotoxicosis is the key to early diagnosis and treatment. A detailed maternal history is invaluable and TRAbs may be of value in a select group of women.
